Sensus Healthcare, Inc. (SRTS) P/E Ratio History
Historical price-to-earnings valuation from 2016 to 2025
Loading P/E history...
SRTS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Sensus Healthcare, Inc. (SRTS) trades at a price-to-earnings ratio of -8.7x, with a stock price of $4.11 and trailing twelve-month earnings per share of $-0.47.
The current P/E is 106% below its 5-year average of 145.2x. Over the past five years, SRTS's P/E has ranged from a low of 5.1x to a high of 1757.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SRTS trades at a 139% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SRTS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SRTS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SRTS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $161B | 57.6 | 2.65 | +23% | |
| $48B | 45.2 | 6.39 | -74% | |
| $100B | 21.6 | - | +31% | |
| $151B | 11.4Lowest | 0.38Best | +134%Best | |
| $84B | 29.2 | - | +55% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SRTS Historical P/E Data (2016–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $4.73 | $0.11 | 44.2x | -70% |
| FY2024 Q4 | $6.92 | $0.41 | 17.0x | -88% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $5.80 | $0.57 | 10.1x | -93% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $5.33 | $0.41 | 13.0x | -91% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $3.80 | $0.29 | 13.2x | -91% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $2.36 | $0.03 | 86.1x | -41% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $3.15 | $0.14 | 23.1x | -84% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $5.21 | $0.37 | 14.1x | -90% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $7.42 | $1.46 | 5.1x | -97% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $12.53 | $1.61 | 7.8x | -95% |
| FY2022 Q2 | $7.68 | $1.51 | 5.1x | -96% | |
| FY2022 Q1 | $10.12 | $1.28 | 7.9x | -95% |
Average P/E for displayed period: 145.2x
See SRTS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRTS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRTS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSRTS — Frequently Asked Questions
Quick answers to the most common questions about buying SRTS stock.
Is SRTS stock overvalued or undervalued?
SRTS trades at -8.7x P/E, below its 5-year average of 145.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SRTS's valuation compare to peers?
Sensus Healthcare, Inc. P/E of -8.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SRTS's PEG ratio?
SRTS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2016-2025.